Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:57:03.892Z.
Calculation as of: 2026-10-06T14:57:03.892Z.
Quote observation: 2026-10-06T14:55:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.46B
Price/FCF Ratio
9.65
TTM Avg
9.98
3Y Avg
22.18
5Y Avg
99.17
Market Cap
$1.44B
Price/FCF Ratio
79.74
TTM Avg
258.29
3Y Avg
258.29
5Y Avg
172.61
Market Cap
$1.51B
Price/FCF Ratio
102.74
TTM Avg
59.64
3Y Avg
44.52
5Y Avg
43.50
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.47B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | 24.03 | 16.96 | 29.77 | 40.80 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 9.65 | 9.98 | 22.18 | 99.17 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | 7.24 | 7.24 | 7.24 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 79.74 | 258.29 | 258.29 | 172.61 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 102.74 | 59.64 | 44.52 | 43.50 |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 5.53 | 5.25 | 8.94 | 38.84 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.15 | 9.29 | 8.77 | 7.33 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
